On October 19, 2022 xCures, Inc. reported their collaboration with mProbe Inc., a premier CLIA-certified targeted proteomics company (Press release, xCures, OCT 19, 2022, View Source [SID1234622168]). mProbe utilizes a proprietary technology platform integrating artificial intelligence and multi-omic diagnostics to transform the diagnosis, prevention, and treatment of complex diseases such as cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As the knowledge of cancer and its treatments advance, it is ever more apparent that every cancer is unique. Through this collaborative partnership, xCures and mProbe will work toward helping cancer patients better understand their tumors’ molecular profile at the proteomic level, allowing precision diagnostics to guide precision medicines by selecting the most effective cancer treatment regimens. mProbe uses a pathologist guided laser microdissection platform to isolate tumor areas from formalin fixed paraffin embedded (FFPE) tissue followed by multiplex mass spectrometry-based quantification of targets for chemotherapy, targeted therapy and immunotherapy. The clinical proteomics test is marketed as OncoOmicsDx.
By integrating xCures’ rich real-world longitudinal clinical data with mProbe’s cancer proteomics panels, the two companies are working to expedite the discovery of predictive, diagnostic, and prognostic biomarkers for cancer.
"We are thrilled to partner with mProbe and to leverage their OncoOmicsDx platform for profiling cancer tissues for patients on our platform," said Mika Newton, CEO of xCures. "We hope our combined efforts towards identifying and expanding upon precision-based actionable drug targets will help cancer patients find the best treatments for their unique cancers."
"When mProbe and xCures join forces in the fight against advanced cancer by offering integrated treatment plans which leverage targeted proteomics, precision diagnostics, artificial intelligence, and predictive modeling, we are giving hope to advanced cancer patients who have exhausted the standard of care." said Peter Chen, CEO of mProbe. "With this new collaboration, we will be able to provide oncologists with actionable proteomic information to help them make informed decisions," said Dr. Sheeno Thyparambil, Ph.D., Senior Director of R&D at mProbe.